Pfizer, Sanofi and Genentech Feature Prominently in the Oncology Edition of PharmaDeals' New Publication Series; Essential Deal

OXFORD, England, October 20, 2011 /PRNewswire/ --

PharmaVentures today announced the launch of PharmaDeals®Essential Deal Trends: Oncology 2011. This new series of reports  is essential reading for everyone involved in developing and commercialising new drugs. The first report in the series focuses on oncology.

Oncology is the single most active deal making therapeutic area in the pharmaceutical and biotechnology industry. With such a high intensity of deal making, executives across the industry need the best information and insight to support their business decisions in this vital drive to make better drugs available for patients. PharmaDeals Essential Deal Trends: Oncology 2011 provides the data and insight that dealmakers need to be as effective as possible. Featuring all the key providers of therapies in the oncology field, including Pfizer, Genentech, Sanofi, Merck, GSK and others, the Essential Deal Trends series provides the most comprehensive deal trends coverage available. Other key deal intensive therapeutic areas including cardiovascular, CNS and respiratory will be published in the following months. Available in the iReport format with over 100 tables and figures in each report, you can extract data and tables for your own analysis and presentations.

Fintan Walton, Chief Executive of PharmaVentures, says, "Deal makers from large pharmaceutical companies to small biotechs tell us they need a high quality publication that helps them best understand the key players and deal trends in this and other vital areas of medicine. We are proud to be able to use our extensive data resources and analytical insight to produce this first in a series of key reports for the industry."

Note to Editors

If you wish to write an article, please contact us for any further information you require.

About the report:

Find out more http://www.pharmadeals.net/edt

Register your interest now

PharmaDeals® Essential Deal Trends is an exciting new deal trend analysis resource from PharmaVentures' experts providing crucial facts, figures and analysis for business decision support

Essential Deal Trends is published monthly addressing each key therapeutic area in turn including Oncology, Cardiovascular, Vaccines, and  CNS For high intensity deal making areas, such as Oncology, we update the report every 6 months, to ensure you can track shifts in trends as they happen. With comprehensive deal type coverage and segmentation by type, phase of development, and product type, Essential Deal Trends is a must-have resource for everyone involved in deal-making.

PharmaDeals Essential Deal Trends: Oncology
ISBN: 978-0-9568270-1-2 (electronic)

View the table of contents

About PharmaVentures

PharmaVentures (http://www.pharmaventures.com) is an international healthcare advisory group providing leadership in all aspects of deals and alliances, from strategy formulations to implementation. The company occupies a special position in the global marketplace because of our track record of successful outcomes, resulting from our unique insight into the world of deal making, our internationally recognised analytical and valuation capabilities, our own proprietary deal making database PharmaDeals® (http://www.pharmadeals.net), containing over 41,000 deal records, and our extensive business relationship network and our outstanding success in M&A transactions. Its subsidiary, PharmaTelevision (http://www.pharmatelevision.com) produces the world's first dedicated online pharmaceutical television channel.

Our Services Cover:

Valuation (for licensing, acquisitions, divestments, fund raising & expert testimonies)

Licensing (In and Out licensing)

M&A (Companies & Assets)

Strategy (commercialisation, deal strategy, due diligence, market entry)

Expert Testimony (Patent Infringement, Deal Disagreements, Taxation, Determining Damages)

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.

PharmaDeals® Is a registered Trade Mark of PharmaVentures Ltd.

For further information, contact:
Lisa Holloway
Senior Direct Marketing Manager
+44-1865-332700
[email protected]

SOURCE PharmaVentures

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.